BIONTECH SE-ADR (BNTX) Stock Fundamental Analysis
USA - NASDAQ:BNTX - US09075V1026 - ADR
103.91 USD
-0.76 (-0.73%)
103.91 USD
0 (0%)
Overall BNTX gets a fundamental rating of 3 out of 10. We evaluated BNTX against 534 industry peers in the Biotechnology industry. Both the profitability and the financial health of BNTX get a neutral evaluation. Nothing too spectacular is happening here. BNTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BNTX had negative earnings in the past year.
BNTX had a negative operating cash flow in the past year.
Of the past 5 years BNTX 4 years were profitable.
BNTX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.60%, BNTX belongs to the top of the industry, outperforming 88.58% of the companies in the same industry.
BNTX has a better Return On Equity (-1.87%) than 90.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.6% | ||
| ROE | -1.87% | ||
| ROIC | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of BNTX (84.15%) is better than 86.89% of its industry peers.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BNTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
2. Health
2.1 Basic Checks
BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BNTX has been increased compared to 5 years ago.
The debt/assets ratio for BNTX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.15 indicates that BNTX is not in any danger for bankruptcy at the moment.
BNTX has a better Altman-Z score (6.15) than 76.03% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
BNTX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: BNTX outperforms 43.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.15 |
ROIC/WACCN/A
WACC7.31%
2.3 Liquidity
A Current Ratio of 8.61 indicates that BNTX has no problem at all paying its short term obligations.
BNTX's Current ratio of 8.61 is fine compared to the rest of the industry. BNTX outperforms 76.03% of its industry peers.
A Quick Ratio of 8.48 indicates that BNTX has no problem at all paying its short term obligations.
The Quick ratio of BNTX (8.48) is better than 75.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.61 | ||
| Quick Ratio | 8.48 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.43% over the past year.
Looking at the last year, BNTX shows a small growth in Revenue. The Revenue has grown by 6.99% in the last year.
Measured over the past years, BNTX shows a very strong growth in Revenue. The Revenue has been growing by 90.73% on average per year.
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%102.64%
3.2 Future
Based on estimates for the next years, BNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.18% on average per year.
Based on estimates for the next years, BNTX will show a small growth in Revenue. The Revenue will grow by 3.47% on average per year.
EPS Next Y-75.93%
EPS Next 2Y-15.72%
EPS Next 3Y-14.25%
EPS Next 5Y14.18%
Revenue Next Year-17.74%
Revenue Next 2Y-4.06%
Revenue Next 3Y-1.44%
Revenue Next 5Y3.47%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BNTX. In the last year negative earnings were reported.
Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BNTX's earnings are expected to decrease with -14.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.72%
EPS Next 3Y-14.25%
5. Dividend
5.1 Amount
BNTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
103.91
-0.76 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners23.44%
Inst Owner Change-0.16%
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap24.98B
Revenue(TTM)2.88B
Net Income(TTM)-345400000
Analysts80
Price Target139.26 (34.02%)
Short Float %6.9%
Short Ratio6.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.65%
Min EPS beat(2)18.78%
Max EPS beat(2)36.51%
EPS beat(4)4
Avg EPS beat(4)107.89%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)138.73%
EPS beat(12)9
Avg EPS beat(12)208.98%
EPS beat(16)12
Avg EPS beat(16)163.75%
Revenue beat(2)2
Avg Revenue beat(2)36.39%
Min Revenue beat(2)1.02%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)46.83%
Min Revenue beat(4)1.02%
Max Revenue beat(4)107.62%
Revenue beat(8)4
Avg Revenue beat(8)11.78%
Revenue beat(12)6
Avg Revenue beat(12)6.28%
Revenue beat(16)9
Avg Revenue beat(16)9.6%
PT rev (1m)0%
PT rev (3m)1.92%
EPS NQ rev (1m)7.08%
EPS NQ rev (3m)40.57%
EPS NY rev (1m)1.27%
EPS NY rev (3m)7.69%
Revenue NQ rev (1m)5.87%
Revenue NQ rev (3m)21.13%
Revenue NY rev (1m)2.35%
Revenue NY rev (3m)5.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.17 | ||
| P/tB | 1.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.66
EYN/A
EPS(NY)-4.3
Fwd EYN/A
FCF(TTM)-12.29
FCFYN/A
OCF(TTM)-8.34
OCFYN/A
SpS13.83
BVpS88.91
TBVpS80.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.6% | ||
| ROE | -1.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.15% | ||
| FCFM | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 270.61% | ||
| Cap/Sales | 28.56% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.61 | ||
| Quick Ratio | 8.48 | ||
| Altman-Z | 6.15 |
F-Score3
WACC7.31%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y-75.93%
EPS Next 2Y-15.72%
EPS Next 3Y-14.25%
EPS Next 5Y14.18%
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%102.64%
Revenue Next Year-17.74%
Revenue Next 2Y-4.06%
Revenue Next 3Y-1.44%
Revenue Next 5Y3.47%
EBIT growth 1Y-1.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.41%
EBIT Next 3Y5.33%
EBIT Next 5Y19.83%
FCF growth 1Y-129.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.63%
OCF growth 3Y-38.43%
OCF growth 5YN/A
BIONTECH SE-ADR / BNTX FAQ
Can you provide the ChartMill fundamental rating for BIONTECH SE-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to BNTX.
Can you provide the valuation status for BIONTECH SE-ADR?
ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (BNTX). This can be considered as Overvalued.
How profitable is BIONTECH SE-ADR (BNTX) stock?
BIONTECH SE-ADR (BNTX) has a profitability rating of 4 / 10.
How financially healthy is BIONTECH SE-ADR?
The financial health rating of BIONTECH SE-ADR (BNTX) is 5 / 10.
Can you provide the expected EPS growth for BNTX stock?
The Earnings per Share (EPS) of BIONTECH SE-ADR (BNTX) is expected to decline by -75.93% in the next year.